About Inovio Pharmaceuticals
Inovio Pharmaceuticals is a publicly listed company based in Plymouth Meeting (United States) founded in 1983 by Joseph Kim. Developer of vaccines for the treatment of cancer and infectious diseases. The company has 134 employees. Inovio Pharmaceuticals has completed 2 acquisitions, including Bioject and VGX Pharmaceuticals. Its chief executive, as recorded, is Joseph Kim. Its website inovio.com draws about 12 thousand monthly visits. Inovio Pharmaceuticals offers products and services including DNA Medicines and CELLECTRA Devices. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is INOVIO PHARMACEUTICALS, INC. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Founded in 1983 and based in Plymouth Meeting, United States, Inovio Pharmaceuticals operates in the biotechnology sector. Synthetic DNA vaccines are developed, delivered via proprietary electroporation to elicit antibody and T-cell responses. The pipeline encompasses immunotherapies targeting cancers of the cervix, head and neck, prostate, breast, lung, and pancreas, alongside protections against infectious diseases including hepatitis, HIV, Ebola, and MERS.
Products & Services of Inovio Pharmaceuticals
Inovio Pharmaceuticals offers a comprehensive portfolio of products and services, including DNA Medicines and CELLECTRA Devices.
Plasmids that enable cells to produce proteins against diseases
Devices for delivering DNA plasmids into cells effectively
Apps and channels of Inovio Pharmaceuticals
its YouTube channel Inovio Pharmaceuticals has 1.04K subscribers and 15 videos.
Videos from Inovio Pharmaceuticals
The most watched videos on Inovio Pharmaceuticals's YouTube channel, Inovio Pharmaceuticals (1.04K subscribers). Click a video to play it here.
More on Inovio Pharmaceuticals.
Funding Insights of Inovio Pharmaceuticals
- Total Rounds 31
- Last Round Grant — $37.6M
- First Round $4.3M
(Jun 2002)
- Investors Count 9
Latest 10 of 31 funding rounds of Inovio Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2020 | $37.6M | Grant | – | – | |
| Jun 2020 | $71M | Grant | – | – | |
| Apr 2020 | $6.9M | Grant | – | – | |
| Mar 2020 | $5M | Grant | – | – | |
| Jan 2020 | $4.04M | Post-IPO | – | – | – |
| Jan 2020 | $9M | Grant | – | – | |
| Sep 2019 | $4.6M | Grant | – | – | |
| Aug 2019 | $15.16M | Post-IPO | – | – | |
| Mar 2019 | $78.5M | Post-IPO | – | – | – |
| Feb 2019 | Post-IPO | – | – | – |
9 investors in total: 9 institutional.
Investors in Inovio Pharmaceuticals
Inovio Pharmaceuticals has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, Korea Investment Holdings and Gates Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare investments are targeted by this private equity firm. | 2017 | cepi.net | Oslo, Norway | |
Investment holding firm established in Seoul in 2003. | 2003 | koreainvestment.com | Seoul, South Korea | |
| 1958 | darpa.mil | United States | ||
Military forces are provided by the U.S. Department of Defense for national security. | defense.gov | Washington, D.C., United States | ||
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States | |
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Cancer vaccines are developed via non-profit biomedical research efforts. | 1892 | wistar.org | United States | |
Administers health care and support for military personnel and operations. | health.mil | Falls Church, United States | ||
| niaid.nih.gov |
Investor details for Inovio Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Inovio Pharmaceuticals
27 people are tracked at Inovio Pharmaceuticals (17 in leadership, 10 in board & advisors); the tracked headcount is 134.
| Name | Role | Group |
|---|---|---|
Joseph Kim | Co-Founder & CEO | Leadership |
J. Joseph Kim | President & CEO | Leadership |
Jeffrey Skolnik | Vice President, Clinical Development | Leadership |
Mark Twyman | Vice President, Commercial | Leadership |
Peter Kies | Chief Financial Officer | Leadership |
Jeffrey C. Richardson | Vice President, Strategic Relations | Leadership |
EJ Brandreth | Vice President, Quality Assurance | Leadership |
Jean D. Boyer | Vice President, Analytical Sciences | Leadership |
Shawn Bridy | VP Business Development | Leadership |
Jacqueline Shea | Chief Operating Officer | Leadership |
Laurent Humeau | Chief Scientific Officer | Leadership |
Keiko Simon | Vice President, Alliance and Program Management | Leadership |
Jessica C. Lee | Vice President, Clinical Operations and Global Integration | Leadership |
Daniel Jordan | Vice President, Device Manufacturing Operations | Leadership |
Robert J. Juba Jr. | Vice President, Biological Manufacturing and Clinical Supply Management | Leadership |
Prakash Bhuyan | Vice President, Clinical Development | Leadership |
Kate E. Broderick | Vice President, R&D | Leadership |
David Weiner | Scientific Advisor | Board & advisors |
Rafi Ahmed | Scientific Advisor | Board & advisors |
Ann C. Miller | Director | Board & advisors |
7 more people are available in the full profile.
Complete people profiles for Inovio Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Inovio Pharmaceuticals
Inovio Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol INO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date12 Feb 1998
- Listed onNASDAQ: INO
- Listed entityInovio Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS45773H4092
- Share price$1.00 (-9.67% on the day) · 2026-10-13
- Market capitalisation$103.2M
- EPS (diluted, trailing year)$-1.18
- Volume (last session)8,473,007
Financials of Inovio Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $65,340 | -$85.0M | -$83.8M |
| 2024 | $217,760 | -$107.2M | -$110.9M |
| 2023 | $832,010 | -$135.1M | -$131.7M |
| 2022 | $10.3M | -$279.8M | -$268.8M |
| 2021 | $1.8M | -$303.7M | -$306.5M |
Detailed financial statements for Inovio Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Inovio Pharmaceuticals
Inovio Pharmaceuticals has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Bioject and VGX Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Needle-free injection therapies are developed for medical drug delivery. | bioject.com | Tigard, United States | 1985 | Mar 2016 | $5.5M | |
DNA-based vaccines for infectious diseases and cancers are developed. | vgxp.com | Blue Bell, United States | 2002 | Jul 2008 | •••• |
Complete acquisition details for Inovio Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Inovio Pharmaceuticals
6 dated milestones of Inovio Pharmaceuticals across 37 years, from founding to its latest funding, stage changes and deals.
- Founded Inovio Pharmaceuticals is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $4.3M.
- Acquisition Acquires VGX Pharmaceuticals.
- Acquisition Acquires Bioject.
- Funding Latest funding round, Grant, of $37.6M.
Competitors of Inovio Pharmaceuticals
Inovio Pharmaceuticals has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Inovio Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Inovio Pharmaceuticals
The website of Inovio Pharmaceuticals (inovio.com) receives about 11.7K visits a month and ranks #1,670,423 among all websites worldwide, #2,247 in Biotechnology and Pharmaceuticals.
- Monthly visits11.7K
▼ 26.5% vs previous month
- Unique visitors6.6K
per month
- Global rank#1,670,423
among all websites
- Category rank#2,247
Health · Biotechnology and Pharmaceuticals
- Bounce rate45%
- Pages per visit1.7
- Average visit1 min 07 sec
- DevicesDesktop 45% · Mobile 55%
Websites whose visitors overlap most with Inovio Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
imvaccine.com | imvaccine.com | 100% | – | ||
takedacalifornia.com | takedacalifornia.com | 79% | – | ||
| novartis.com | 78% | 948.8K | #58,822 | View details | |
iderapharma.com | iderapharma.com | 76% | – | ||
| mabvax.com | 75% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 24 similar websites and full traffic analytics for Inovio Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 24 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as Inovio Pharmaceuticals (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Inovio Pharmaceuticals
Complete news archive for Inovio Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Inovio Pharmaceuticals
Inovio Pharmaceuticals was founded in 1983 and raised its 1st funding round 19 years after it was founded.
Inovio Pharmaceuticals is headquartered in Plymouth Meeting, United States. It is registered at Plymouth Meeting, Pennsylvania, United States.
Joseph Kim is the CEO of Inovio Pharmaceuticals, as recorded in our data. They have also founded this company.
Inovio Pharmaceuticals has 134 employees.
Annual revenue of Inovio Pharmaceuticals is $65.34K as on Dec 31, 2025.
Founded in 1983 and based in Plymouth Meeting, United States, Inovio Pharmaceuticals operates in the biotechnology sector. Synthetic DNA vaccines are developed, delivered via proprietary electroporation to elicit antibody and T-cell responses. The pipeline encompasses immunotherapies targeting cancers of the cervix, head and neck, prostate, breast, lung, and pancreas, alongside protections against infectious diseases including hepatitis, HIV, Ebola, and MERS.
Inovio Pharmaceuticals offers DNA Medicines and CELLECTRA Devices.
Yes, Inovio Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol INO.
Inovio Pharmaceuticals has made 2 acquisitions, including Bioject, and VGX Pharmaceuticals.
Inovio Pharmaceuticals has 9 investors. Key investors include NIH, Korea Investment Holdings, Gates Foundation, DARPA, and CEPI.
Inovio Pharmaceuticals operates through Inovio Pharmaceuticals, Inc..